Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Change in Receivables (2016 - 2025)

IGC Pharma (IGC) has disclosed Change in Receivables for 16 consecutive years, with -$61000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Receivables fell 481.25% to -$61000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$20000.0, a N/A change, with the full-year FY2025 number at -$7000.0, down 128.0% from a year prior.
  • Change in Receivables was -$61000.0 for Q3 2025 at IGC Pharma, down from $53000.0 in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $78000.0 in Q4 2022 to a low of -$96000.0 in Q1 2023.
  • A 5-year average of -$5333.3 and a median of -$8500.0 in 2021 define the central range for Change in Receivables.
  • Biggest YoY gain for Change in Receivables was 581.82% in 2025; the steepest drop was 481.25% in 2025.
  • IGC Pharma's Change in Receivables stood at $25000.0 in 2021, then skyrocketed by 212.0% to $78000.0 in 2022, then plummeted by 143.59% to -$34000.0 in 2023, then surged by 64.71% to -$12000.0 in 2024, then crashed by 408.33% to -$61000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Change in Receivables are -$61000.0 (Q3 2025), $53000.0 (Q2 2025), and -$12000.0 (Q4 2024).